Have any questions? +91-891- 2878787, +91-891- 2551811, info@mgcancerhospital.com


We, Mahatma Gandhi Cancer Hospital & Research Institute, have organized the “The FIRST AP state conference on NEUROENDOCRINE TUMORS” on 8th-April-2018 in Visakhapatnam. During this event, the best minds of this region related to NETs discussed on the related topics!

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

The World Health Organization (WHO) classification scheme places neuroendocrine tumors into three main categories, which emphasize the tumor grade rather than the anatomical origin:

  • Well-differentiated neuroendocrine tumors, further subdivided into tumors with benign and those with uncertain behavior
  • Well-differentiated (low grade) neuroendocrine carcinomas with low-grade malignant behavior
  • Poorly differentiated (high grade) neuroendocrine carcinomas, which are the large cell neuroendocrine and small cell carcinomas.

Grand Inauguration of “The FIRST AP State Conference on Neuroendocrine Tumors” by Dr CV Rao, Vice Chancellor of NTRUHS, Dr CH. Lakshmana Rao of APMC and Dr Jakir Ali of ANMPI graced the occasion, along with Conference Organising Chairman Dr Murali Krishna Voonna and organizing Secretary Dr Raghava Kashyap.

Professor Mukta Ramadwar explained about NETs and grades of NETsWhat are Neuroendocrine Tumors (NETs)? How common/rare are they? Do they run in Families?

Professor Mukta Ramadwar, from Tata Memorial Hospital, Mumbai, explained about NETs, their classification and grades of NETs.

Dr. Archi Agarwal, from Tata Memorial Hospital, Mumbai, explained about ever increasing role of Positron Emission Tomography with 68Ga-DOTATOC and 18F-FDG in staging and characterizing #NETs and how it prognosticates and guides treatment decisions.

Dr. B Surendra Kumar explained about Radiological Diagnosis - CT/MRI

Dr. B Surendra Kumar, Seven Hills Hospital, Visakhapatnam explained about ‘Cross-sectional imaging with CT & MRI in the detection of NET’.

Dr. A. Chalapati Rao explained about ‘Endoscopy guided diagnosis & it’s role in Tissue Acquisition in NETs’.

Dr. Rinkesh Bansal talk on treatment of NETs

Dr. Rinkesh Bansal from Fortis Hospital, Gurgaon explained his personal experience on treatment of NETs.


Dr. Raja Pramanik, Assistant Professor, Medical Oncology from All India Institute of Medical Sciences, Delhi explained about the treatment options for patients with metastatic NETs.


Dr. Sundeep Lakhtakia from Asian Institute of Gastroenterology explained about ‘The exciting field of non-surgical therapeutic procedures’.

DSC_1377-Talk-by-Dr-KarthikDr. Karthik Chandra Vallam, Surgical Oncologist from Mahatma Gandhi Cancer Hospital, trained in Robotic Surgeryexplained about ‘The intricacies of surgical management of GEP NETs’.

Dr. Ramakant Bhargav talk on Surgical management of Endocrine related NETDr. Ramakant Bhargav, Endocrine Surgeon specializing in minimal access surgeries, explained about the ‘Surgical management of Pheochromocytoma, Paraganglioma and Medullary Thyroid cancer’.

Symptoms of NETs are the most troubling for the patients and can sometimes be life-threatening.

Dr. Rakesh Reddy talk on Management of symptoms related to the NETsDr. Rakesh Reddy B from Mahatma Gandhi Cancer Hospital, explained about ‘Management of symptoms related to the NETs and better quality of life to be provided to the patients’.

‘It is not the end of the road for patients with metastatic NETs’.

Dr. K Raghava Kashyap talk on PRRTDr. K Raghava Kashyap, Nuclear Medicine Specialist from Mahatma Gandhi Cancer Hospital explained about the ‘Role of 177 Lutetium Based Peptide Receptor Radionuclide Therapy (PRRT) for patients with metastatic NETs’ with metastatic NETs and how they can be benefited from the treatment.

Panel Discussion on ‘NETs’ towards the end of the conference on Neuroendocrine Tumors.